CooperCompanies stock (US21664P1039): earnings update and outlook after latest quarterly figures

CooperCompanies has reported new quarterly results and updated its outlook, drawing investor attention to growth in contact lenses and women’s health. What the latest numbers reveal and what is driving the business model now.

CooperCompanies has recently released new quarterly figures that shed light on its current growth trajectory in vision care and women’s health, including developments at CooperVision and CooperSurgical, according to Cooper investor relations as of 03/07/2025 and coverage from Reuters as of 03/07/2025. The update has put the focus on demand trends for premium contact lenses as well as the company’s efforts to reshape its fertility and women’s health portfolio.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: CooperCompanies
• Sector/industry: Medical devices, vision care, women’s health
• Headquarters/country: San Ramon, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Contact lenses, fertility and obstetric products
• Home exchange/listing venue: New York Stock Exchange (ticker: COO)
• Trading currency: US dollar (USD)

CooperCompanies: core business model

CooperCompanies operates as a specialty healthcare group with two key business segments: CooperVision and CooperSurgical. CooperVision focuses on soft contact lenses and related products for correcting vision issues such as myopia, hyperopia and astigmatism, including daily disposable and frequent replacement lenses, according to the company’s segment description in its annual report for the fiscal year ended 10/31/2024 published on 12/18/2024 on its website, as cited by Cooper investor relations as of 12/18/2024. CooperSurgical targets women’s health and fertility markets with devices, consumables and services used in obstetrics, gynecology and assisted reproductive technology.

In its core lens business, CooperCompanies emphasizes specialty and premium designs rather than low-margin commodity products. The portfolio includes silicone hydrogel materials and multifocal designs that address presbyopia, as well as toric lenses for astigmatism, aiming at fitters and eye-care professionals who want differentiated solutions, according to product information presented by the company and summarized by Moody’s as of 09/05/2024. This positioning gives the group exposure to structural trends such as increasing screen time, growing myopia prevalence in younger populations and rising adoption of daily disposable lenses.

The women’s health arm extends the business model beyond vision care and is aimed at hospitals, clinics and fertility centers. It covers in-vitro fertilization (IVF) consumables, genetic testing services, surgical instruments and related products used in gynecological procedures. While this segment has faced portfolio changes and integration challenges in recent years, CooperCompanies sees it as a complementary pillar that can benefit from demographic trends such as delayed parenthood and rising demand for fertility treatments, as discussed in management commentary during recent earnings calls summarized by Barron’s as of 03/08/2025.

Main revenue and product drivers for CooperCompanies

Revenue at CooperCompanies is largely driven by CooperVision, which generates the majority of group sales through contact lenses sold to eye-care professionals and optical chains worldwide. Within this segment, key product families include daily disposable lenses such as MyDay and clariti as well as monthly and two-week replacement lenses like Biofinity, which are marketed for comfort and oxygen permeability, according to portfolio descriptions in the fiscal 2024 Form 10-K filed with the US Securities and Exchange Commission on 12/18/2024, referenced by SEC filing as of 12/18/2024. The company reports that growth in these franchise lines has been supported by eye-care practitioners shifting patients toward silicone hydrogel and daily disposable modalities.

In the latest reported quarter for the period ended 01/31/2025, CooperCompanies highlighted that CooperVision delivered mid-to-high single-digit organic revenue growth, with particularly solid momentum in daily disposable and toric lenses, according to the earnings release published on 03/07/2025 on its investor relations site, as cited by Cooper Q1 2025 earnings as of 03/07/2025. Management pointed to healthy demand in the Americas and strong uptake in Asia-Pacific markets, where rising incomes and increased awareness of eye health support lens adoption.

CooperSurgical, while smaller than CooperVision, represents an important diversification for the group’s revenue stream. In that same quarter ended 01/31/2025, the women’s health and fertility segment recorded moderate year-on-year growth, with particular strength in IVF consumables, though some other product categories saw more muted performance, according to the same Q1 2025 earnings communication recorded by Nasdaq earnings overview as of 03/08/2025. The company has been working to refine its portfolio and improve profitability by focusing on higher-margin products and streamlining operations.

Profitability metrics remain a focus for investors, particularly given the need to balance investments in innovation and marketing with returns to shareholders. For the fiscal year ended 10/31/2024, CooperCompanies reported revenue growth and solid adjusted operating margins, supported by scale in its contact lens franchise and ongoing cost discipline, according to the fiscal 2024 results release on 12/18/2024, as outlined by MarketWatch financials as of 12/19/2024. However, integration expenses and investments in systems and regulatory compliance in the women’s health business have weighed on reported earnings at times, which remains a point of attention in quarterly reports.

Industry trends and competitive position

The contact lens market in which CooperVision competes is concentrated and competitive, with major global players such as Johnson & Johnson Vision Care, Alcon and Bausch + Lomb also vying for market share. Industry research firms expect mid-single-digit annual growth for the global soft contact lens market over the medium term, driven by demographic trends and rising disposable incomes, according to a contact lens market study released by Grand View Research on 06/10/2024 and summarized by Grand View Research as of 06/10/2024. CooperCompanies aims to differentiate itself through specialty designs and strong relationships with eye-care professionals rather than relying solely on mass retail channels.

Within women’s health and fertility, the company competes with a mix of diversified medical device groups and niche specialists. Demand for IVF-related products is influenced by clinic volumes and reimbursement frameworks, which can vary significantly between geographies. Regulatory requirements and quality standards are high, especially for genetic testing and lab consumables, which can create barriers to entry but also raise complexity and compliance costs. CooperSurgical’s position in this segment is supported by its installed base of equipment and established relationships with fertility centers, as mentioned in sector commentary by Fierce Medtech as of 02/14/2025.

CooperCompanies’ competitive strategy also involves ongoing investment in research and development. In the fiscal year ended 10/31/2024, the company allocated a mid-single-digit percentage of revenue to R&D, focusing on new lens materials, myopia management solutions and enhancements to women’s health technologies, according to the 2024 Form 10-K filed on 12/18/2024, as documented in SEC company filings as of 12/18/2024. This is intended to support long-term growth but can moderate near-term margins if project timelines lengthen or commercialization takes longer than expected.

Why CooperCompanies matters for US investors

For US-based investors, CooperCompanies represents exposure to resilient healthcare demand with a strong foothold in the domestic market and diversified international operations. The stock is listed on the New York Stock Exchange under the ticker COO, providing access via one of the most liquid equity markets globally, as reported by NYSE company overview as of 03/10/2025. CooperVision’s large presence in the US contact lens market ties part of the company’s performance to consumer health spending and insurance coverage trends in the United States.

The business also offers a way to participate in global growth themes through a US-listed vehicle. A significant portion of CooperCompanies’ revenue is generated outside the United States, with Europe and Asia-Pacific contributing meaningfully to sales, as outlined in the regional breakdown in the fiscal 2024 annual report published on 12/18/2024, referenced by Cooper annual report as of 12/18/2024. This international diversification can help balance regional swings in demand but also introduces currency and geopolitical risk.

From a portfolio construction perspective, CooperCompanies is often classified in healthcare or medical device allocations and may be considered by investors looking for exposure to defensive sectors that can perform more steadily across economic cycles. However, the stock’s performance is also influenced by sector-specific factors such as reimbursement changes, regulatory approvals and competition in medical devices, which can drive volatility around earnings dates, as noted in sector commentary by Morningstar equity research as of 03/09/2025.

Risks and open questions

Despite its diversified operations, CooperCompanies faces several risks that investors may monitor closely. Competition in contact lenses is intense, and pricing pressure could emerge if large rivals pursue aggressive discounting strategies or if regulatory changes affect reimbursement and consumer behavior. Additionally, any product quality or safety issues could lead to recalls, litigation or reputational damage, particularly in medical devices and fertility products where patient outcomes are at stake, as highlighted in risk factor disclosures in the 2024 Form 10-K filed on 12/18/2024, summarized by SEC Form 10-K as of 12/18/2024.

Regulatory and reimbursement dynamics also pose uncertainties, especially in women’s health and fertility. Changes in insurance coverage, public funding or clinical guidelines can influence procedure volumes and demand for IVF and related products. Furthermore, integration of past acquisitions and the ongoing optimization of the CooperSurgical portfolio carry execution risk. If synergies do not materialize as planned or if restructuring efforts take longer than expected, margins could remain under pressure longer-term, according to commentary from credit rating agencies following fiscal 2024 results, cited by S&P Global Ratings as of 01/29/2025.

Macroeconomic conditions and foreign exchange movements add another layer of uncertainty. A strong US dollar can dampen reported revenue growth from international markets when sales are translated back into dollars, and economic slowdowns could affect elective procedures or discretionary spending on premium lenses. These factors can contribute to share price volatility around macro data releases and central bank decisions, which is relevant for investors timing entry and exit points, as observed in sector performance analyses by Bloomberg markets as of 03/11/2025.

Key dates and catalysts to watch

Investors following CooperCompanies typically track the company’s quarterly earnings releases and conference calls, during which management updates guidance, discusses segment performance and provides commentary on market conditions. For the current fiscal year, the company has scheduled earnings announcements roughly every three months, with the next key date expected around early June 2025 for fiscal second-quarter results, based on the historical reporting pattern referenced in the Q1 2025 earnings calendar entry on Nasdaq earnings calendar as of 03/08/2025. Exact dates are typically confirmed in investor relations updates and regulatory filings shortly before the events.

Other potential catalysts include regulatory approvals or clearances for new contact lens designs or women’s health products, outcomes of clinical or post-market studies, and any significant portfolio changes such as divestitures or acquisitions. Analyst days or capital markets events, where management lays out medium-term growth plans and financial targets, can also influence investor sentiment and valuation multiples. Monitoring these dates can help market participants understand when fresh information might prompt revisions to earnings expectations, as highlighted in coverage of past CooperCompanies events by Seeking Alpha events tracker as of 03/09/2025.

Conclusion

CooperCompanies combines a global contact lens franchise with a diversified women’s health and fertility portfolio, offering exposure to structural healthcare trends and international growth from a US stock market listing. Recent quarterly results have underscored the strength of CooperVision’s premium lens offerings, while CooperSurgical continues to undergo portfolio refinement and operational adjustments. At the same time, the group faces competitive, regulatory and execution risks that can influence margins and share price volatility. For investors, understanding the balance between growth prospects in vision care, the evolution of the women’s health business and the broader macro backdrop remains central to assessing the company’s longer-term trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.